Literature DB >> 19018717

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Nahoko Kaniwa1, Yoshiro Saito, Michiko Aihara, Kayoko Matsunaga, Masahiro Tohkin, Kouichi Kurose, Jun-ichi Sawada, Hirokazu Furuya, Yukitoshi Takahashi, Masaaki Muramatsu, Shigeru Kinoshita, Masamichi Abe, Hiroko Ikeda, Mariko Kashiwagi, Yixuan Song, Mayumi Ueta, Chie Sotozono, Zenro Ikezawa, Ryuichi Hasegawa.   

Abstract

INTRODUCTION: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening severe cutaneous adverse reactions. Recently, strong associations of HLA-B*1502 and HLA-B*5801 with carbamazepine- and allopurinol-induced severe cutaneous adverse reactions were found in Han Chinese patients, respectively, but ethnic differences in the associations have been reported. The objective of this study is to clarify the involvement of HLA-B*1502 and HLA-B*5801 in Japanese SJS/TEN patients.
METHODS: HLA-B genotyping was performed on 58 Japanese SJS/TEN patients between July 2006 and April 2008 from multicenters in Japan.
RESULTS: There were no HLA-B*1502 carriers among 58 SJS/TEN patients. This patient group included seven carbamazepine-related and 11 aromatic anti-epileptic agent-related SJS/TEN patients. In addition, there were five HLA-B*5801 carriers, which included four allopurinol-related SJS/TEN patients.
CONCLUSION: While HLA-B*1502 is unlikely to be associated with carbamazepine-related or aromatic anti-epileptic agent-related SJS/TEN, HLA-B*5801 was significantly associated with allopurinol-related SJS/TEN in Japanese.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018717     DOI: 10.2217/14622416.9.11.1617

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  88 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Authors:  S G Leckband; J R Kelsoe; H M Dunnenberger; A L George; E Tran; R Berger; D J Müller; M Whirl-Carrillo; K E Caudle; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2013-05-21       Impact factor: 6.875

2.  Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study.

Authors:  Sarah F Keller; Na Lu; Kimberly G Blumenthal; Sharan K Rai; Chio Yokose; Jee Woong J Choi; Seoyoung C Kim; Yuqing Zhang; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2018-04-13       Impact factor: 19.103

Review 3.  Genetic Testing in Clinical Settings.

Authors:  Nora Franceschini; Amber Frick; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2018-04-11       Impact factor: 8.860

4.  Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.

Authors:  Suran L Fernando; Andrew J Broadfoot
Journal:  CMAJ       Date:  2009-11-23       Impact factor: 8.262

5.  Is it time for drug sensitivity genetic screening?

Authors:  Carl W Bazil
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

6.  Clinical use of pharmacogenomic tests in 2009.

Authors:  Leslie J Sheffield; Hazel E Phillimore
Journal:  Clin Biochem Rev       Date:  2009-05

7.  Tag SNPs for HLA-B alleles that are associated with drug response and disease risk in the Chinese Han population.

Authors:  X Liu; J Sun; H Yu; H Chen; J Wang; H Zou; D Lu; J Xu; S L Zheng
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550

Review 8.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

9.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 10.  A review of pharmacogenetics of adverse drug reactions in elderly people.

Authors:  Maurizio Cardelli; Francesca Marchegiani; Andrea Corsonello; Fabrizia Lattanzio; Mauro Provinciali
Journal:  Drug Saf       Date:  2012-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.